Showing posts with label Aortic Valve Market Share. Show all posts
Showing posts with label Aortic Valve Market Share. Show all posts

How are Government Initiatives Driving Aortic Valve Market?

Every year, cardiovascular diseases (CVD) lead to 17.9 million human fatalities, as per the World Health Organization (WHO). With so many components, the heart is itself a complex organ to manage medically, with each component having its own set of diseases and disorders. It could be an electrical problem (malfunctioning of the sinoatrial or atrioventricular node in the cardiac pacemaker), clogging of the coronary arteries with plaque, valve destruction, inflammation of the chambers or cardiac muscle, myopathy (muscle death), infection or a structural defect, such as the arrhythmogenic right ventricular cardiomyopathy (ARVC).


Valve replacement surgeries can be done the open way or minimally invasive way. Of these, minimally invasive surgeries (MISs) are performed in higher numbers than open procedures, as they account for significantly smaller incisions, lower blood loss and pain, and shorter hospital stays. Further, with patients becoming more conscious about their appearance, the nasty scars caused by open surgeries are putting these procedures out of preference around the world. There are two MIS approaches to aortic valve replacement — transfemoral and transapical — of which the former is preferred due to the larger diameter of the femoral artery, which makes threading the catheter easier.



Globally, Europe has been the largest aortic valve market till now, as aortic valve stenosis accounts for a high prevalence rate in regional nations. Additionally, new products and surgical technologies are getting approvals from regulatory authorities, which are revolutionizing cardiothoracic and vascular surgery in the continent. Even in the coming years, the procurement of aortic valves by healthcare centers will increase the fastest here, with the rapid improvements in the medical infrastructure.

Hence, as the prevalence of valvular heart disease increases across the world, so will the demand for artificial aortic valves.

Share:

Aortic Valve Market and its Growth Prospect in the Near Future


The insulin delivery device market size is projected to reach $15.6 billion by 2022, growing at a CAGR 6.6% between 2016-2022.
The increasing prevalence of diabetes, growing geriatric population, increasing prevalence of obesity, technological of drug delivery devices and increasing awareness of diabetic care are driving the growth of the market.
In terms of type, the insulin delivery device market is segmented into insulin pen, insulin syringe, insulin pump and others. The insulin pen segment accounted for the major market share in the global market in 2015, and the insulin pump segment is expected to witness the highest growth during 2016-2022.
Request for a sample of this research report: 
Insulin pen needle has single use, although many diabetic patients re-use needle for delivery of insulin. The re-use of needle could lead to bacterial growth on the needle, risk of lipohypertrophy and risk of breaking fine tip of needle. Similarly, the risk associated with jet injectors are accuracy of insulin dosage and improper injection. Improper injection of insulin can lead to altered absorption level of insulin in the blood stream and bruising. Hence, these risks and complications associated with delivery devices are inhibiting the growth of the insulin delivery device market.

Some of the key companies operating in the insulin delivery device market include Novo Nordisk A/S, Medtronic PLC, Abbott Laboratories, Eli Lilly and Company, Insulet Corporation, Sanofi S.A., Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd., Animas Corporation, B. Braun Melsungen AG, and Ypsomed Holdings AG.

Share:

Popular Posts